IP Library Granted Patent US 10,864,195
Granted Patent B2
US 10,864,195 · App. 15/819,523 · Granted Dec 15, 2020

Topical localized isoxazoline formulation

Inventors: Stefan Fuchs (Essenheim, DE); Anja Regina Heckeroth (Elsheim, DE); Ramona Müller (Eich, DE); Heike Williams (Offenbach am Main, DE); Hartmut Zoller (Hochheim, DE)
Assignee: Intervet Inc.
A61K31/42A01N43/80A61K9/0014A61K9/0017A61K31/366A61K45/06A61K47/08A61K47/10A61K47/12A61K47/20A61K47/22A61P33/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,864,195
App. No.
15/819,523
Granted
Dec 15, 2020
Kind
B2
Abstract

This invention provides topical localized formulations comprising an isoxazoline compound and a pharmaceutically or veterinary acceptable liquid carrier vehicle comprising N,N-diethyl-3-methylbenzamide as a solvent and an improved method for controlling, and preventing parasite infestation in animals.

Claims (48)

1. A topical localized formulation for the treatment of parasite infestation in animals which comprises an effective amount of at least one isoxazoline compound of the Formula (I)

wherein

R 1 is 3-CF3, and 5-C1; n is 2;

R 2 is CF 3 ;

T is

Q is X-NR 3 R 4 ;

X is C(O);

R 3 is -CH 2 -C(O)-NH-CH 2 -CF 3 ;

and R 4 is H

or

R 1 is 3-, 4-, and 5-Cl; n is 3;

R 2 is CF 3 ;

T is

Q is X-NR 3 R 4 ;

X is C(O);

Y is methyl;

R 3 is -CH 2 -C(O)-NH-CH 2 -CF 3 ;

and R 4 is H;

and a veterinary acceptable liquid carrier vehicle wherein the liquid carrier vehicle comprises N,N-diethyl-3-methylbenzamide as a solvent.

2. The topical localized formulation according to claim 1 , wherein the formulation comprises 1 to 50% N,N-diethyl-3-methylbenzamide.

3. The topical localized formulation according to claim 1 wherein the liquid carrier vehicle comprises N,N-diethyl-3-methylbenzamide as solvent and a co-solvent selected from the group consisting of dimethyl sulfoxide, acetone, dimethylacetamide, ethyl alcohol, eucalyptol, dipropylene glycol monomethyl ether, methylethyl ketone, glycofurol, ethyl-L-lactate, and a mixture of at least two of these co-solvents.

4. The topical localized formulation according to claim 3 wherein the liquid carrier vehicle comprises N,N-diethyl-3-methylbenzamide as solvent and a mixture of at least two of acetone, ethyl-L-lactate, dimethyl sulfoxide, dimethylacetamide and glycofurol.

5. The topical localized formulation according to claim 3 wherein there is a weight/weight ratio of the cosolvent/solvent in the spot-on composition and the weight/weight ratio of the cosolvent/solvent is between 4/1 and 1/5.

6. The topical localized formulation according to claim 1 , wherein the formulation further comprises an effective amount of one or more compounds selected from a macrocyclic lactone compound or an insect growth regulator compound.

7. The topical localized formulation of claim 3 , wherein the formulation further comprises an effective amount of one of more compounds selected from a macrocyclic lactone compound or an insect growth regulator compound.

8. The topical localized formulation of claim 7 , wherein the macrocyclic lactone compound is selected from ivermectin, moxidectin, milbemycin, selamectin, emamectin, latidectin and lepimectin or a salt thereof and the insect growth regulator compound is selected from fenoxycarb, lufenuron, diflubenzuron, novaluron, triflumuron, fluazuron, cyromazine, methoprene and pyriproxyfen.

9. The topical localization formulation of claim 3 , wherein the veterinary acceptable liquid carrier comprises a co-solvent of at least two of ethyl-L-lactate, dimethyl sulfoxide, dimethylacetamide and glycofurol.

10. The topical localized formulation of claim 1 , wherein

R 1 is 3-CF 3 , and 5-Cl; n is 2;

R 2 is CF 3 ;

T is

Q is X-N R 3 R 4 ;

X is C(O);

R 3 is -CH 2 -C(O)-NH-CH 2 -CF 3 ;

and R 4 is H.

11. The topical localized formulation of claim 1 , wherein

R 1 is 3-, 4-, and 5-C1; n is 3;

R 2 is CF 3;

T is

Q is X-N R 3 R 4 ;

X is C(O);

Y is methyl;

R 3 is -CH 2 -C(O)-NH-CH 2 -CF 3 ;

and R 4 is H.

12. A method for treatment of parasite infestation of an animal comprising spot-on or pour-on administration of a localized topical formulation of claim 1 .

13. The method of claim 12 wherein the veterinary acceptable liquid carrier comprises a co-solvent of at least two of acetone, ethyl-L-lactate, dimethyl sulfoxide, dimethylacetamide and glycofurol.

14. The method of claim 12 wherein the topical localized formulation comprises additionally an effective amount of a macrocyclic lactone compound and/or an insect growth regulator compound.

15. The method of claim 14 wherein the macrocyclic lactone compound is selected from ivermectin, moxidectin, milbemycin, selamectin, emamectin, latidectin and lepimectin or a salt thereof and the insect growth regulator compound is selected from fenoxycarb, lufenuron, diflubenzuron, novaluron, triflumuron, fluazuron, cyromazine, methoprene and pyriproxyfen.

Assignments (3)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: FUCHS, STEFAN; HECKEROTH, ANJA REGINA; MULLER, RAMONA; WILLIAMS, HEIKE; ZOLLER, HARTMUT
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 046460/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 046460/0589 →
Priority Claims (1)
EP 10197089 · Dec 27, 2010 · regional
Continuity (5)
Continuation 15359036 · Nov 22, 2016
Continuation 14867641 · Sep 28, 2015
Division 13996263
Provisional Application 61430240 · Jan 6, 2011
Related Publication 20180085352A1 · Mar 29, 2018
Cited By (3)
US 12,304,903 US 12,544,336 US 12,655,138